Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 40030, China
NCT Number: NCT06720454
The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Wuhan, Hubei, 40030, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From January 2019 to January 2024
In this study, 68 pancreatic ductal adenocarcinoma tissues were used to detect the gene expression by multiple immunofluorescence staining
Tiejun Ying
Other
Multiplex Immunofluorescence Staining of Pathological Tissue Microarray
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07329920
Circulating Tumor Cells (CTCs), Neoadjuvant Therapy
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06481397
Pancreatic Ductal Adenocarcinoma (PDAC)
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT06147154
Pancreatic Ductal Adenocarcinoma (PDAC)
Jinan, Shandong, China
View Trial DetailsNCT03811652
Bronchial Neoplasms, Carcinoma
Huntersville, North Carolina, United States
View Trial Details